Persistent malignant stem cells in del(5q) myelodysplasia in remission.
Tehranchi R. et al, (2010), N Engl J Med, 363, 1025 - 1037
ROLE OF BIALLELIC C/EBPALPHA MUTATIONS AND FLT-3 ITD IN INITIATION AND MAINTENANCE OF AML
Reckzeh K. et al, (2010), EXPERIMENTAL HEMATOLOGY, 38, S116 - S117
The RNA binding protein Larp1 regulates cell division, apoptosis and cell migration.
Burrows C. et al, (2010), Nucleic Acids Res, 38, 5542 - 5553
Stability of measurement of the immature platelet fraction.
Ruisi MM. et al, (2010), Am J Hematol, 85, 622 - 624
Quinone oxidoreductase-2-mediated prodrug cancer therapy.
Middleton MR. et al, (2010), Sci Transl Med, 2
HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning.
Mead AJ. et al, (2010), Blood, 115, 5147 - 5153
MEGAKARYOCYTES SUPPORT THE INTEGRITY OF BONE MARROW (BM) VASCULAR NICHES AND ATTRACT METASTATIC TUMOUR CELLS TO THE BM IN MURINE MODELS OF METASTASIS AND IN PATIENTS WITH CARCINOMA
Psaila B. et al, (2010), HAEMATOLOGICA, 95, 477 - 478
MEGAKARYOCYTES SUPPORT THE INTEGRITY OF BONE MARROW (BM) VASCULAR NICHES AND ATTRACT METASTATIC TUMOUR CELLS TO THE BM IN MURINE MODELS OF METASTASIS AND IN PATIENTS WITH CARCINOMA
Psaila B. et al, (2010), HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 95, 477 - 478
A phase I study to determine the comparative bioavailability of two different oral formulations of the PARP inhibitor, olaparib (AZD2281), in patients with advanced solid tumors.
Molife LR. et al, (2010), JOURNAL OF CLINICAL ONCOLOGY, 28
Phase I pharmacokinetic and pharmacodynamic evaluation of the vascular disrupting agent OX14503 in patients with advanced solid tumors.
Zweifel M. et al, (2010), JOURNAL OF CLINICAL ONCOLOGY, 28
Phase I study of OSI-906, dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in combination with erlotinib (E) in patients with advanced solid tumors.
Macaulay VM. et al, (2010), JOURNAL OF CLINICAL ONCOLOGY, 28
Selective inhibition of proliferating endothelial cells: A phase I study of the novel organoarsenical compound GSAO in patients with advanced solid tumors
Kumaran G. et al, (2010), JOURNAL OF CLINICAL ONCOLOGY, 28
Non-cancer medications for patients with incurable cancer: time to stop and think?
Hall PS. et al, (2010), Br J Gen Pract, 60, 243 - 244
Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma.
Helfrich I. et al, (2010), J Exp Med, 207, 491 - 503
A reply to evidence-based radiation oncology: oesophagus.
Gillies RS. et al, (2010), Radiother Oncol, 94, 387 - 388
Factors predicting outcome for advanced gastroesophageal cancer in elderly patients receiving palliative chemotherapy.
Lord SR. et al, (2010), Clin Oncol (R Coll Radiol), 22, 107 - 113
The vascular phenotype, vessel stabilization and maturation affect the resistance to anti-angiogenic therapy in malignant melanoma
Helfrich I. et al, (2010), EUROPEAN JOURNAL OF CELL BIOLOGY, 89, 44 - 44
Concomitant medications in cancer patients: should we be more active in their management?
Lord S. et al, (2010), Ann Oncol, 21
Presentation and survival of patients with severe acute kidney injury and multiple myeloma: a 20-year experience from a single centre.
Haynes RJ. et al, (2010), Nephrol Dial Transplant, 25, 419 - 426